Treatment parameterization
Treatment parametization employs descriptions of country-specific treatment pathways, drug utilization studies and resource use analysis to help estimate direct and indirect costs of health conditions and frame the potential impacts of new treatments. Treatment parametization and burden of illness studies are undertaken to support the reimbursement processes, measure the impact of competitor products and inform ongoing pharmacoeconomic analysis after a product’s efficacy has been demonstrated. These studies are useful for predicting the potential impact of new therapeutics or policies on disease burden. Alternatively they can be used to monitor changes after the introduction of new therapies, in the post-marketing phase, using real-world effectiveness and safety data.
At Oxford Outcomes we can provide robust and validated burden of illness and chronic disease models, our model construction is based upon the estimates of incidence, prevalence, morbidity, mortality, resource use and treatment safety and efficacy. We incorporate iterative validation procedures to ensure that our model outputs accurately reflect the clinical picture and have high face validity. To carry out treatment parametization at Oxford Outcomes we measure the burden of illness and resource utilization with a combination of the following methods:
- Retrospective chart reviews.
- Physician surveys.
- Interviews and advisory boards.
- Patient survey, interview or focus groups.
- Longitudinal analysis of administrative data.
Our Epidemiology team has experience completing targeted burden of illness studies using a combination of the above techniques for the Canadian market, and multinational burden of illness studies using longitudinal analysis of administrative data. We have in depth knowledge of the best data sources in North America and Europe and exploit this to offer a complete and rigorous treatment parametization service, either as a stand alone product or as part of a broader package.